Elrexfio
Elrexfio ingredients
| Active ingredient | Strength |
|---|---|
| Elranatamab | 76 mg/1.9mL, 44 mg/1.1mL |
What Elrexfio is used for
The FDA lists the approved uses on the official label (below). In the EU, elranatamab is approved as Elrexfio for:
Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Elrexfio
- Generic name
- Elranatamab-bcmm
- Made by
- Pfizer Laboratories Div Pfizer Inc
- Forms
- Injection, Solution
- Given
- Subcutaneous
- FDA approval
- Biologic licence (BLA) BLA761345
- On the US market since
- 2023
Official information
- MedlinePlus drug information (search for Elranatamab-bcmm)
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Elrexfio?
Elrexfio (Elranatamab-bcmm) is a specialist medicine made by Pfizer Laboratories Div Pfizer Inc, approved by the US FDA.
What are the ingredients of Elrexfio?
Elrexfio contains Elranatamab (76 mg/1.9mL, 44 mg/1.1mL).
Is Elrexfio approved in Europe?
The same active substance is approved in the EU as Elrexfio.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA